RT Journal Article
SR Electronic
T1 Observational Study of the Efficiency of Treatments in Patients Hospitalized with Covid-19 in Madrid
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.17.20155960
DO 10.1101/2020.07.17.20155960
A1 Bernaola, Nikolas
A1 Mena, Raquel
A1 Bernaola, Ander
A1 Carballo, Cesar
A1 Lara, Antonio
A1 Bielza, Concha
A1 Larrañaga, Pedro
YR 2020
UL http://medrxiv.org/content/early/2020/07/21/2020.07.17.20155960.abstract
AB Background Many different treatments were heavily administered to patients with COVID-19 during the peak of the pandemic in Madrid without robust evidence supporting them.Methods We examined the association between sixteen treatments in four groups (steroids, antivirals, antibiotics and immunomodulators) and intubation or death. Data were obtained from patients that were admitted to an HM hospital with suspicion of COVID-19 until 24/04/2020, excluding unconfirmed diagnosis, those who were admitted before the epidemic started in Madrid, had an outcome that was not discharge or death or died within 24 hours of presentation. We compared outcomes between treated and untreated patients using propensity-score caliper matching.Results Of 2,307 patients in the dataset, 679 were excluded. Of the remaining 1,645 patients, 263 (16%) died and 311 (18.9%) died or were intubated. Except for hydroxychloroquine and prednisone, patients that were treated with any of the medications were more likely to go through an outcome of death or intubation at baseline. After propensity matching we found an association between treatment with hydroxychloroquine and prednisone and better outcomes (hazard ratios with 95% CI of 0.83 ± 0.06 and 0.85 ± 0.03). Results were similar in multiple sensitivity analyses.Conclusions In this multicenter study of patients admitted with COVID-19 hydroxychloroquine and prednisone administration was found to be associated with improved outcomes. Other treatments were associated with no effect or worse outcomes. Randomized, controlled trials of these medications in patients with COVID-19 are needed to avoid heavy administration of treatments with no strong evidence to support them.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was not fundedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics approval was obtained by the hospital network collecting the data. Ethics board from UPM exempted us from asking for approval due to the anonymized nature of the data.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available on request from the HM hospital network COVID data save lives by sending a project proposal and being approved. https://www.hmhospitales.com/coronavirus/covid-data-save-lives